GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today highlighted the growing strategic importance of scalable domestic vaccine manufacturing infrastructure and diversified vaccine supply capabilities amid a series of escalating global infectious disease developments.
Recent public health events, including the World Health Organization’s declaration of a Public Health Emergency of International Concern (PHEIC) related to the ongoing Ebola outbreak involving the Bundibugyo strain, continued international spread of Clade I mpox, and recent hantavirus-related public health concerns, underscore the increasingly dynamic nature of global biodefense and pandemic preparedness requirements.
“These developments reinforce the importance of scalable and flexible vaccine preparedness infrastructure,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “GeoVax’s primary strategic focus remains the advancement of GEO-MVA, our Modified Vaccinia Ankara (MVA) mpox and smallpox vaccine candidate, which we believe is well aligned with growing global emphasis on diversified vaccine supply, domestic manufacturing capability, and long-term biodefense preparedness.”
GeoVax is advancing GEO-MVA to support global orthopoxvirus preparedness efforts and help address the need for expanded and diversified vaccine supply infrastructure. The Company recently announced positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway toward potential regulatory approval. This pivotal Phase 3 trial is scheduled to initiate in Q4 ’26, with data results anticipated by mid-2027.
GeoVax believes recent infectious disease developments further reinforce the strategic importance of: diversified vaccine supply infrastructure; scalable domestic manufacturing capabilities; rapid-response vaccine platform technologies; and long-term investment in biodefense preparedness.
The Company also noted that the broader applicability of the MVA platform has been demonstrated across multiple infectious disease settings, including prior preclinical Ebola/hemorrhagic fever virus vaccine studies in which GeoVax’s MVA-based Ebola-Zaire vaccine candidate demonstrated complete protection in non-human primate lethal-challenge studies following Ebola virus exposure.
“Recent events continue to demonstrate that preparedness infrastructure cannot remain reactive or narrowly focused on individual outbreak cycles,” continued Mr. Dodd. “We believe the advancement of scalable domestic MVA-based manufacturing capability represents an important strategic objective for strengthening future biodefense readiness.”
The implications of this announcement are significant. For the biotechnology industry, it highlights the need for investment in flexible manufacturing platforms that can quickly adapt to emerging threats. For public health agencies and governments, it reinforces the urgency of building domestic vaccine production capacity to reduce reliance on foreign supply chains, especially as global health emergencies become more frequent. For investors, GeoVax’s progress with GEO-MVA—now on a clear regulatory path—positions the company as a key player in the biodefense space, with potential to secure government contracts and partnerships. The broader world benefits from a more resilient vaccine infrastructure that can respond rapidly to outbreaks, potentially saving lives and preventing economic disruption.
For more information, visit www.geovax.com.
